Assessment the effect of trehalose in patients with Lewy body dementia

To assess the effect of trehalose on cognitive abillity in patients with Lewy body dementia and evaluation of key proteins in the protein interaction network of LBD

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250317065107N1

Enrollment

Registered

2025-05-11

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lewy body dementia. Dementia with Lewy bodies

Interventions

Intervention 1: Intervention group: Trehalose (Shanxxi Fruiterco Co. Ltd. China) will be administered orally at a dose of 20 grams per day for up to three months. Intervention 2: Control group: Place

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals with Lewy body dementia Individuals must consent to participate in the study

Exclusion criteria

Exclusion criteria: Having atypical parkinsonism syndromes Having Alzheimer Having other neurodegenerative diseases

Design outcomes

Primary

Measure	Time frame
Cognitive impairment. Timepoint: Evaluation is done at the beginning of the study and at the twelfth week. Method of measurement: Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) will be used for cognitive assessment.	—

Secondary

Measure	Time frame
Serum level of a-Synuclein. Timepoint: At baseline and after 12 weeks from intervention. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Del Azad

Mashhad University of Medical Sciences

DelAzadK4001@mums.ac.i009 51 38002288

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026